Cellectis S.A. (CLLS) — SEC Filings

Q: What are the key financial highlights for Cellectis S.A.?

Key financial highlights for Cellectis S.A. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Cellectis S.A.?

Key executives at Cellectis S.A. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Cellectis S.A. stock?

Risk factors for Cellectis S.A. (CLLS) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Cellectis S.A.?

Forward-looking statements and predictions from Cellectis S.A. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Cellectis S.A.. Recent 6-K filing on Dec 15, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Cellectis S.A. on SEC EDGAR

Overview

Cellectis S.A. (CLLS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 8, 2025: Cellectis S.A. filed a Form 6-K on December 8, 2025, reporting for the month of December 2025. The company, a biopharmaceutical firm based in Paris, France, is a foreign private issuer and files its annual reports under Form 20-F. This filing does not contain specific financial figures or operationa

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 50 neutral. The dominant filing sentiment for Cellectis S.A. is neutral.

Filing Type Overview

Cellectis S.A. (CLLS) has filed 46 6-K, 1 20-F/A, 2 20-F, 1 SC 13D/A with the SEC between Apr 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

6-K Filing — 6-K · Dec 15, 2025
Cellectis S.A. Files December 2025 6-K Report — 6-K · Dec 8, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on December 8, 2025, reporting for the month of December 2025. The company, a biopharmaceutical firm based in Paris, France, is
Cellectis S.A. Re-files Exhibit 4.1.3 to Form 6-K — 6-K · Dec 5, 2025 Risk: low
Cellectis S.A. is re-filing Exhibit 4.1.3 to its Form 6-K, originally submitted on December 5, 2025. The purpose of this re-filing is to correct or update infor
Cellectis S.A. Files Form 6-K — 6-K · Nov 19, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on November 19, 2025, reporting as a foreign private issuer. The filing indicates that the company is submitting its report unde
Cellectis S.A. Files Form 6-K — 6-K · Nov 7, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on November 7, 2025, reporting information as a foreign private issuer. The filing incorporates by reference previous registrati
6-K Filing — 6-K · Nov 3, 2025
6-K Filing — 6-K · Oct 31, 2025
Cellectis S.A. Files 6-K Regarding BALLI-01 Study — 6-K · Oct 17, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on October 16, 2025, reporting information related to its BALLI-01 Study. This filing incorporates information into existing reg
Cellectis S.A. Files Form 6-K — 6-K · Oct 16, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on October 16, 2025, reporting as a foreign private issuer. The company, based in Paris, France, is involved in the biological p
Cellectis S.A. Files Form 6-K — 6-K · Oct 7, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on October 7, 2025, reporting as a foreign private issuer. The company, incorporated in France with its principal executive offi
Cellectis S.A. Files Form 6-K with SEC — 6-K · Aug 4, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on August 4, 2025, reporting as a foreign private issuer. The filing indicates that the company will file its annual reports und
Cellectis S.A. Files 6-K Report — 6-K · Aug 4, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on August 4, 2025, reporting information as of the same date. This filing is a report of a foreign private issuer and is incorpo
Cellectis S.A. Files Routine 6-K Report — 6-K · Jul 28, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on July 28, 2025, reporting as a foreign private issuer. The company, based in Paris, France, is involved in the biological prod
Cellectis S.A. Files Routine 6-K Report — 6-K · Jun 26, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on June 26, 2025, reporting as a foreign private issuer. The company, based in Paris, France, is involved in the biological prod
Cellectis S.A. Files 6-K, Reports Board Changes — 6-K · Jun 26, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on June 26, 2025, reporting changes to its Board of Directors. This filing is incorporated by reference into several of their ex
Cellectis S.A. Files Routine 6-K Report — 6-K · May 21, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on May 21, 2025, to report information as a foreign private issuer. The filing does not contain specific financial figures or op
Cellectis S.A. Files 6-K for Board Change — 6-K · May 21, 2025 Risk: low
Cellectis S.A. announced a board change on May 21, 2025. The information regarding this change is incorporated by reference into several of their existing regis
Cellectis S.A. Files 6-K, Confirms 20-F Filing — 6-K · May 12, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on May 12, 2025, reporting as a foreign private issuer. The company, based in Paris, France, is involved in biological products.
Cellectis Files 6-K, Incorporates Exhibit 99.1 — 6-K · May 12, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on May 12, 2025, reporting information for its registration statements. The filing incorporates by reference information from Ex
Cellectis S.A. Files Routine 6-K Report — 6-K · May 6, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on May 6, 2025, to report its activities as a foreign private issuer for the month of May 2025. The company, based in Paris, Fra
Cellectis S.A. Files Routine 6-K Report — 6-K · Apr 28, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on April 28, 2025, to report information for the month of April 2025. The company, a biopharmaceutical firm based in Paris, Fran
Cellectis Files 6-K, Incorporates Registration Statements — 6-K · Mar 31, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on March 31, 2025, to incorporate by reference its registration statements on Forms F-3 and S-8. The filing does not contain new
Cellectis S.A. Files 20-F/A Amendment — 20-F/A · Mar 14, 2025 Risk: low
Cellectis S.A. filed an amendment (20-F/A) to its annual report for the fiscal year ended December 31, 2024. The filing, dated March 14, 2025, is an amendment t
Cellectis S.A. Files 2024 Annual Report — 20-F · Mar 14, 2025 Risk: medium
Cellectis S.A. filed its 20-F annual report for the fiscal year ending December 31, 2024. The report details the company's financial position, including cash an
Cellectis S.A. Files Form 6-K for March 2025 — 6-K · Mar 7, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on March 7, 2025, to report information for the month of March 2025. This filing includes a press release (Exhibit 99.1) which i
Cellectis S.A. Files February 2025 6-K Report — 6-K · Feb 24, 2025 Risk: low
Cellectis S.A. filed a Form 6-K on February 24, 2025, for the month of February 2025. The filing indicates that Cellectis is a foreign private issuer and files
Cellectis S.A. Files Form 6-K for December 2024 — 6-K · Dec 10, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on December 10, 2024, to report information for the month of December 2024. This filing includes a press release that will be in
Cellectis Files Form 6-K with SEC — 6-K · Nov 5, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on November 5, 2024, to report information as a foreign private issuer. The filing indicates that Cellectis is submitting its re
Cellectis Files 6-K, Incorporates Exhibits — 6-K · Nov 4, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on November 4, 2024, reporting information for its registration statements. The filing incorporates by reference Exhibit 99.1 in
Cellectis S.A. Files 6-K, Confirms 20-F Reporting — 6-K · Oct 30, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on October 30, 2024, to report its status as a foreign private issuer filing annual reports under Form 20-F. The filing provides
Cellectis S.A. Files Routine 6-K Disclosure — 6-K · Oct 22, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on October 22, 2024, to report its status as a foreign private issuer. The company, based in Paris, France, is required to file
Cellectis S.A. Files September 2024 6-K Report — 6-K · Sep 3, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on September 3, 2024, to report information for the month of September 2024. The company, a biopharmaceutical firm based in Pari
Cellectis S.A. Files Form 6-K with SEC — 6-K · Aug 26, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on August 26, 2024, reporting its status as a foreign private issuer. The filing confirms that Cellectis, headquartered in Paris
Cellectis S.A. Files Form 6-K Reporting Status — 6-K · Aug 7, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on August 7, 2024, reporting its status as a foreign private issuer. The company, based in Paris, France, is involved in biologi
Cellectis Files 6-K, Incorporates Previous Filings — 6-K · Aug 6, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on August 6, 2024, reporting information as a foreign private issuer. The filing incorporates by reference previous registration
Cellectis S.A. Files Form 6-K — 6-K · Aug 1, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on August 1, 2024, to report its status as a foreign private issuer filing annual reports under Form 20-F. The filing provides b
Cellectis Files Routine 6-K, Confirms 20-F Reporting — 6-K · Jul 25, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on July 25, 2024, to report its status as a foreign private issuer. The filing confirms that Cellectis, headquartered in Paris,
Cellectis S.A. Shareholders Meet June 28, 2024 — 6-K · Jun 28, 2024 Risk: low
Cellectis S.A. (the "Company") held its Combined General Meeting of Shareholders on June 28, 2024. The voting results from this meeting are attached as Exhibit
Cellectis S.A. Files 6-K Report — 6-K · Jun 28, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on June 28, 2024, to report a press release dated June 28, 2024. The filing does not contain specific financial figures or opera
Cellectis S.A. Files Form 6-K, Announces Press Release — 6-K · Jun 20, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on June 20, 2024, to report a press release dated the same day. The filing does not contain specific financial figures or operat
Cellectis S.A. Files Form 6-K with Press Release — 6-K · Jun 12, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on June 12, 2024, to report a press release dated June 12, 2024. The filing does not contain specific financial figures or opera
Cellectis S.A. Files Form 6-K — 6-K · Jun 4, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on June 4, 2024, to report a press release dated June 4, 2024. The filing does not contain specific financial figures or operati
Cellectis S.A. Files Form 6-K with Press Release — 6-K · May 29, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on May 29, 2024, to report a press release dated May 29, 2024. The filing does not contain specific financial figures or operati
Cellectis S.A. Files Form 6-K — 6-K · May 28, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on May 28, 2024, reporting a press release dated May 27, 2024. The filing does not contain specific financial figures or operati
Cellectis Files 6-K Report, Incorporates Prior Filings — 6-K · May 28, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on May 28, 2024, to report information as a foreign private issuer. The filing incorporates by reference previous registration s
Cellectis to Hold Shareholder Meeting June 28 — 6-K · May 24, 2024 Risk: low
Cellectis S.A. announced its Combined General Meeting of Shareholders will be held on June 28, 2024, at 2:30 p.m. Paris time. The meeting will take place at the
Bpifrance Files Cellectis S.A. 13D/A Amendment — SC 13D/A · May 21, 2024 Risk: medium
Bpifrance Participations S.A. filed an amendment (No. 4) to its Schedule 13D on May 21, 2024, regarding its holdings in Cellectis S.A. The filing indicates a ch
Cellectis S.A. Files 6-K, Incorporates Past Filings — 6-K · May 6, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on May 6, 2024, to report information for the month of May 2024. This filing incorporates by reference previous registration sta
Cellectis S.A. Files 6-K with Management Update — 6-K · May 3, 2024 Risk: low
Cellectis S.A. filed a Form 6-K on May 2, 2024, reporting a management update as of April 29, 2024. The filing incorporates information into existing registrati
Cellectis S.A. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · Apr 29, 2024 Risk: medium
Cellectis S.A. (CLLS) filed a Foreign Annual Report (20-F) with the SEC on April 29, 2024. Cellectis S.A. filed its 20-F annual report for the fiscal year endin

Risk Profile

Risk Assessment: Of CLLS's 47 recent filings, 0 were flagged as high-risk, 3 as medium-risk, and 44 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Sophie Paquin
John C. Partigan
Lloyd H. Spencer

Top Tags

sec-filing (22) · foreign-private-issuer (20) · regulatory-filing (13) · reporting (9) · registration-statement (7) · filing (6) · press-release (6) · administrative (4) · 6-k (3) · regulatory-update (2)

Key Numbers

Fiscal Year End: 2024 — The report covers the fiscal year ending on this date.
Filing Date: 20250314 — The amendment was filed on this date.
SEC File Number: 001-36891 — Identifies the company's registration with the SEC
Film Number: 24969612 — Internal SEC processing number for the filing.
Date for Class B Convertible Preferred Shares: 2023-11-14 — Specific date mentioned in filing
Previous Fiscal Year End: 2022-12-31 — Context for financial comparisons

Related Companies

CXT

Frequently Asked Questions

What are the latest SEC filings for Cellectis S.A. (CLLS)?

Cellectis S.A. has 50 recent SEC filings from Apr 2024 to Dec 2025, including 46 6-K, 2 20-F, 1 20-F/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CLLS filings?

Across 50 filings, the sentiment breakdown is: 50 neutral. The dominant sentiment is neutral.

Where can I find Cellectis S.A. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Cellectis S.A. (CLLS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Cellectis S.A.?

Financial highlights for Cellectis S.A. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for CLLS?

The investment thesis for CLLS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Cellectis S.A.?

Key executives identified across Cellectis S.A.'s filings include Sophie Paquin, John C. Partigan, Lloyd H. Spencer.

What are the main risk factors for Cellectis S.A. stock?

Of CLLS's 47 assessed filings, 0 were flagged high-risk, 3 medium-risk, and 44 low-risk.

What are recent predictions and forward guidance from Cellectis S.A.?

Forward guidance and predictions for Cellectis S.A. are extracted from SEC filings as they are enriched.